ライフサイエンスコーパス: thymoma

1 R2-IgG dual seropositive patients (one-third thymoma).

2 objective was response rate in patients with thymoma.

3 PFS and overall survival than patients with thymoma.

4 ity of lung, breast, or ovarian carcinoma or thymoma.

5 ty in patients with octreotide scan-positive thymoma.

6 bodies may expand the serological profile of thymoma.

7 s integrated upstream from c-myc in a second thymoma.

8 usceptible to the spontaneous development of thymoma.

9 ans has been implicated in lympho-epithelial thymoma.

10 for the treatment of patients with advanced thymoma.

11 CSF and frequently present with a malignant thymoma.

12 1957 and 1997 with a pathologic diagnosis of thymoma.

13 second primary malignancies in patients with thymoma.

14 nction by distinct mechanisms in suppressing thymoma.

15 n the management of early stage and advanced thymoma.

16 ation are not impaired in the development of thymoma.

17 ure locally advanced, unresectable malignant thymoma.

18 (60.0%) in the second group had a malignant thymoma.

19 is suggested for patients with unresectable thymoma.

20 s in the management of patients with limited thymoma.

21 oline receptor (AChR) antibodies and 45% had thymoma.

22 isease, and Good syndrome is associated with thymoma.

23 rolled, 25 with thymic carcinoma and 16 with thymoma.

24 diagnostic evaluation of patient with cystic thymoma.

25 ndidiasis, ectodermal dystrophy syndrome) or thymoma.

26 apy is well-tolerated and active in relapsed thymoma.

27 derwent complete resection of a stage IVA B3 thymoma.

28 derstand the somatic genetic architecture of thymoma.

29 receptors), were prevalent in patients with thymoma.

30 ut it has not been reached for patients with thymoma.

31 is responsible for the development of T cell thymomas.

32 a thymic carcinoma and four were noninvasive thymomas.

33 from supF-tagged proviruses in two resulting thymomas.

34 the more rapid onset and higher incidence of thymomas.

35 in culture and in primary retrovirus-induced thymomas.

36 ing paraneoplastic phenomena associated with thymomas.

37 T cell maturation while going on to develop thymomas.

38 no extensive sequencing has been reported in thymomas.

39 /sec and 1.29 x 10(-3) mm(2)/sec), high-risk thymoma (1.16 x 10(-3) mm(2)/sec and 1.14 x 10(-3) mm(2)

40 both readings (P = .01 and .20) of low-risk thymoma (1.30 x 10(-3) mm(2)/sec and 1.29 x 10(-3) mm(2)

41 ipheral nerve hyperexcitability and 1 with a thymoma; 3 were given immunotherapies.

42 Most of the large lymphomas were thymomas (65%), and these lymphomas developed in less th

43 occur in myasthenia gravis, especially with thymoma, a myopathy associated with Waldenstrom's macrog

44 970T>A) in GTF2I at high frequency in type A thymomas, a relatively indolent subtype.

45 luation revealed the recurrence of malignant thymoma, accompanied by refractory arrhythmia.

46 s on the basis of MG diagnosis and severity: thymoma alone (T), thymoma-associated MG with mild and m

47 Few NSMBCs were observed in patients with thymoma alone, with these cells being diffusely distribu

48 for TCR gene translocations in p53-deficient thymomas, although abundant aneuploidy involving frequen

49 cloned proviral U3 sequences from the first thymoma and generated an infectious chimeric virus, MCF

50 for malignancy were reclassified as benign (thymoma and histoplasmosis).

51 as detected in 30 of 116 patients (26%) with thymoma and in 30 of 36 patients (83%) with disseminated

52 e detected, likely induced by the underlying thymoma and increasing susceptibility to both severe COV

53 as myasthenia gravis can be associated with thymoma and Lambert-Eaton myasthenic syndrome with small

54 ia; infections, particularly B19 parvovirus; thymoma and other solid tumors; or a variety of other di

55 patients with histopathologically confirmed thymoma and serum available to test for synaptic autoant

56 ibodies to voltage-gated potassium channels; thymoma and small-cell lung cancer are the most common u

57 le, as well as in subgroups of patients with thymoma and those older than 40 years of age.

58 A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our un

59 9.8) and 5.0 (95% CI, 3.0 to 8.3) months for thymoma and thymic carcinoma cohorts, respectively.

60 t any point, which we analysed separately in thymoma and thymic carcinoma cohorts.

61 e toxicity in patients with advanced type B3 thymoma and thymic carcinoma progressing after chemother

62 Patients with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy h

63 ifferentiate low-risk thymoma from high-risk thymoma and thymic carcinoma were 1.25 and 1.22 x 10(-3)

64 e a type B3 thymoma, and two a mixed type B3 thymoma and thymic carcinoma.

65 g axitinib in patients with advanced type B3 thymoma and thymic carcinoma.

66 patients with advanced previously untreated thymoma and thymic carcinoma.

67 49 patients were enrolled (37 with thymomas and 12 with thymic carcinomas) who received a m

68 in culture and in primary retrovirus-induced thymomas and encodes a nuclear, sequence-specific DNA-bi

69 ugmented in tumour endothelium such as mouse thymomas and human lung tumours.

70 e remaining 45 patients had newly-identified thymomas and one had a lymphoma.

71 Five had thymomas and one had an endometrial adenocarcinoma.

72 a high predisposition to developing cancer (thymomas) and immune abnormalities (impaired early thymo

73 rmalities and systemic tumours (teratoma and thymoma), and they do not develop SIADH-like hyponatraem

74 Of the 41 patients enrolled, 25 had thymoma, and 16 had thymic carcinoma; patients had a med

75 table adenocarcinoma, melanoma, sarcoma, and thymoma, and also a transgenic model of spontaneous brea

76 pecific CTL to the P815 mastocytoma, the EL4 thymoma, and the Lewis lung carcinoma is dependent on tu

77 = .014) between low-risk thymoma, high-risk thymoma, and thymic carcinoma.

78 ents had a thymic carcinoma, three a type B3 thymoma, and two a mixed type B3 thymoma and thymic carc

79 Thymomas are infrequent and relatively indolent mediasti

80 The thymomas are monoclonal and highly malignant and display

81 Thymic carcinomas and thymomas are neoplasms of the epithelial cells of the th

82 erologic parallels to APS-I in patients with thymomas are not explained purely by deficient TSAg tran

83 Immune histologic analyses indicate that the thymomas are of epithelial cell origin.

84 , we tested a second cohort of patients with thymoma as well as patients without either thymoma or kn

85 ithmic usefulness as negative predictors for thymoma (as recognized for neuronal voltage-gated calciu

86 oma tumor microenvironment (TME), leading to thymoma-associated autoimmune diseases.

87 The mechanisms underlying thymoma-associated immunodeficiency are largely unknown,

88 rate clinical symptoms (T + MGL), and severe thymoma-associated MG (T + MGH).

89 thenia gravis (MG) severity in patients with thymoma-associated MG (TMG) and the distribution of B ce

90 mmune hyperactivity, and immune tolerance in thymoma-associated MG in both the peripheral blood and t

91 G diagnosis and severity: thymoma alone (T), thymoma-associated MG with mild and moderate clinical sy

92 antibodies as well as age-based distinction, thymoma-associated, and immune checkpoint inhibitor-indu

93 present the first comprehensive view of a B3 thymoma at whole genome and transcriptome levels.

94 ce which spontaneously and heritably develop thymomas at a very high penetrance.

95 om a proximal Lck promoter construct develop thymomas at an early age, whereas transgenic mice expres

96 as carried a higher number of mutations than thymomas (average of 43.5 and 18.4, respectively).

97 Thymoma behaves as a rather indolent tumor, with most de

98 that multiple lineages of tumors, including thymoma, breast cancer, colon cancer, and melanoma cell

99 mutation in 82% of type A and 74% of type AB thymomas but rarely in the aggressive subtypes, where re

100 in-12) are often identified in patients with thymoma, but opportunistic infections develop in only so

101 with small cell lung carcinoma or malignant thymoma can develop an autoimmune response against the C

102 es between NSMBCs and SMBCs in PB and TME of thymomas can synergistically determine MG severity in pa

103 0) and B7.2 (CD86) cDNAs into the EL4 T cell thymoma cell line and examined the transfectants for the

104 The EL-4 thymoma cell line contains a peptidase which converts be

105 When expressed in the murine thymoma cell line EL4, activation of this mutant results

106 e coreceptors and their respective mRNA in a thymoma cell line model.

107 line 32Dcl3, and the prolactin-dependent rat thymoma cell line Nb2.

108 n, made by whole cell fusion between a mouse thymoma cell line, and to microcell hybrids made with a

109 Murine thymoma cell lines expressing mutated forms of the mdr1b

110 Sensitive EL4 mouse thymoma cells (s-EL4) respond to phorbol esters with gro

111 Stimulation of sensitive EL4 mouse thymoma cells (s-EL4) with phorbol esters results in pro

112 se the silencer and enhancer in CD4-negative thymoma cells and double-negative immature thymocytes.

113 mitogen-activated protein kinase p38 in EL4 thymoma cells and in freshly isolated murine lymphocytes

114 e Schlafen family members in fibroblasts and thymoma cells either retards or ablates cell growth.

115 in phorbol ester-sensitive EL4 (S-EL4) mouse thymoma cells have been identified as the p120 c-Cbl pro

116 isozyme inhibition were obtained using mouse thymoma cells overexpressing the fas gene (LF(+)).

117 Previous studies of mouse thymoma cells showed that GlcNAc-PI de-N-acetylase activ

118 treated mice bearing tumors derived from EG7 thymoma cells that express the well-characterized chicke

119 xpressed granzyme A and directly lysed YAC-1 thymoma cells through granule exocytosis.

120 e released enzymatically from the surface of thymoma cells transfected with cDNAs encoding TCR-alpha

121 ion against syngeneic, ganglioside GD2+ EL-4 thymoma cells was observed.

122 Incubation of murine thymocytes or S49 mouse thymoma cells with dibutyryl-cAMP, 8-bromo-cAMP, cholera

123 omain and that, unlike the result with mouse thymoma cells, both PIG-L and GlcNAc-PI-de-N-acetylase a

124 In AKR1010 thymoma cells, Nrarp overexpression blocks CBF-1-depende

125 In phorbol ester-sensitive EL4 thymoma cells, phorbol-12-myristate 13-acetate (PMA) ind

126 r but is unable to elongate in CD4(-) CD8(+) thymoma cells.

127 the induction of apoptosis in WEHI7.2 mouse thymoma cells.

128 C57BL/6 mice and fusion of splenocytes with thymoma cells.

129 plex, and their assembly with calnexin in BW thymoma cells.

130 methasone-induced apoptosis of mouse WEHI7.2 thymoma cells.

131 l large granular lymphocytic (LGL) leukemia, thymoma, chronic lymphocytic leukemia, and non-Hodgkin's

132 ese questions based on an index patient with thymoma, chronic visceral leishmaniasis, myasthenia grav

133 In the thymoma cohort, five (14%) of 37 patients (95% CI 5-29)

134 90% CI, 24.5% to 62.8%) were observed in the thymoma cohort; 10 patients had stable disease.

135 /cAMP pathway was investigated in the murine thymoma-derived T-cell line, EL4.IL-2.

136 Nine (24%) of 37 patients with thymoma developed autoimmune conditions during treatment

137 tion was dispensable for tumorigenesis since thymomas developed with or without the RAG-1 or RAG-2 ge

138 which Notch1IC oncogenes could contribute to thymoma development and maintenance.

139 how that V(D)J recombination is critical for thymoma development in these mice.

140 erological testing as an aid to preoperative thymoma diagnosis.

141 , a strain in which 100% of the mice develop thymoma due to thymocyte-specific inactivation of p53 by

142 eover, expression of a high level of CD80 on thymoma EL4 cells conveys immunity in mice with a target

143 the importance of these mechanisms in murine thymoma EL4/EG7 cells.

144 nduction of antitumor immunity to the T cell thymoma, EL4.

145 he overlap of myasthenia, neuromyotonia, and thymoma, emphasizing the importance of appropriate tumor

146 atory for pre-operative evaluation of cystic thymoma, final diagnosis still remains surgical.

147 The available data suggest that thymoma formation in these mice results as a consequence

148 liferative expansion of T cells in vitro and thymoma formation in vivo were prevented by the absence

149 both readings used to differentiate low-risk thymoma from high-risk thymoma and thymic carcinoma were

150 c mice overexpressing the c-myc oncogene and thymomas from mice deficient for the ataxia telangiectas

151 In addition, the thymomas generally express high levels of c-myc.

152 significantly higher in the TMG-high than in thymoma group.

153 s, B7W-transfected J558 plasmocytoma and EL4 thymoma grow significantly more slowly than those transf

154 tumor-draining lymph nodes (TDLN) during EL4 thymoma growth, this event was insufficient to promote t

155 or unresectable, locally advanced, malignant thymoma has been poor.

156 To date, only seven patients (33.3%) with thymoma have died, compared with 16 patients (69.6%) wit

157 composite outcome was associated with active thymoma (hazard ratio [HR] 3.6, 95% confidence interval

158 art of the tumor (P = .014) between low-risk thymoma, high-risk thymoma, and thymic carcinoma.

159 otonia as the heralding symptom of recurrent thymoma in a patient with myasthenia gravis.

160 Molecular analyses of the resultant thymomas indicated that the U3 region of MCF ProEn was g

161 hese proviruses are thought to contribute to thymoma induction by enhancer-mediated deregulation of c

162 identified and classified 193 patients with thymoma into 4 groups: (1) lacking neurological autoimmu

163 Cystic thymoma is a rare variant of thymic neoplasm characteriz

164 d syndrome (GS) is a rare condition in which thymoma is associated with hypogammaglobulinemia.

165 Thymoma is closely related to MG, although the underlyin

166 Thymoma is commonly recognized in association with paran

167 Thymoma is often associated with myasthenia gravis (MG).

168 Thymoma is the most common tumor of the anterior mediast

169 Thymoma is the most common tumor of the anterior-superio

170 cell focus-inducing (MCF) viruses to induce thymomas is determined, in part, by transcriptional enha

171 Molecular pathology of thymomas is poorly understood.

172 TSAgs showed the expected underexpression in thymomas, levels were increased for four of the five TSA

173 ty is associated with magnitude of troponin, thymoma, low QRS voltage, depressed LVEF, and cardiomusc

174 est x-ray or computed tomography to rule out thymoma, lymphocyte immunophenotype studies, anti-nuclea

175 ated mutations in this patient suggests that thymomas may evolve through mechanisms distinctive from

176 Of the 193 patients with thymoma, mean patient age was 52 years and did not signi

177 lts were further supported in vivo using EL4 thymoma metastasis as a model of T-cell migration.

178 RNA was translated in the presence of murine thymoma microsomes which, in contrast to the canine panc

179 ulate immunity against tumors in a syngeneic thymoma model.

180 either the pathologic diagnosis (presence of thymoma) nor the age at surgery proved to be negative pr

181 assembled around tertiary lymphoid tissue in thymomas of patients with TMG.

182 pendent PDAC cells, inactivated c-akt murine thymoma oncogene homolog 1 signaling via mammalian targe

183 required for KRAS activation of c-akt murine thymoma oncogene homolog 1-mammalian target of rapamycin

184 rator-activated receptor gamma, v-AKT murine thymoma oncogene homolog 2, zinc metalloprotease and lip

185 Of 16 patients with thymoma, one (6%, 95% CI 0.2-30.2) had a partial respons

186 r, with most deaths from causes unrelated to thymoma or its direct treatment.

187 h thymoma as well as patients without either thymoma or known anti-interleukin-12 who had unusual inf

188 ogic diagnosis of limited-stage unresectable thymoma or thymic carcinoma were eligible.

189 Forty-two patients with advanced thymoma or thymic carcinoma were entered onto the trial,

190 tients with histologically confirmed type B3 thymoma or thymic carcinoma, with advanced stage of dise

191 Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months

192 B cells, were determined in 79 patients with thymoma or TMG.

193 than daratumumab and isatuximab against EL4 thymoma or VK*MYC myeloma cells overexpressing human CD3

194 d further, we screened 247 patients with MG, thymoma, or both for clinical features and organ-specifi

195 nitially seen with a neoplasm (lung, breast, thymoma, or ovary).

196 A metastatic thymoma patient achieved a complete and durable response

197 Thymoma patients should be monitored for potentially lif

198 relevant acquired T cell immunodeficiency in thymoma patients that is distinct from Good's syndrome.

199 ively, in 49 of 121 (40%) and 10 of 121 (8%) thymoma patients, but clinical features seldom occurred

200 mocyte populations obtained from three other thymoma patients.

201 criteria included pure ocular MG, suspected thymoma, previous thymectomy, and prior noncorticosteroi

202 bearing established TGF-beta-OVA-expressing thymomas, produce high amounts of IFN-gamma and sensitiz

203 entification of gene(s) which participate in thymoma progression, as well as a model system for scree

204 Patient 1 had a thymoma recurrence, but in patient 2 no tumour has been

205 n promoting EG7 (an OVA transfection the EL4 thymoma) rejection in mice.

206 Overall, the thymoma-related mortality rate was 14%; the nonthymoma-r

207 predictors of recurrence and survival after thymoma resection.

208 nt of murine Notch-1 as capable of rendering thymomas resistant to glucocorticoid-induced apoptosis.

209 None of the six patients without pure thymoma responded.

210 patients achieved partial response (both had thymoma; response rate, 8%; 95% CI, 2.2% to 25%), 25 had

211 -19) hospitalization he was diagnosed with a thymoma, retrospectively identified as already present a

212 eristic of APS-I patients, and we assayed 26 thymoma samples for transcripts for AIRE and 16 peripher

213 (AIRE) gene, and myasthenia gravis (MG) with thymoma, show intriguing but unexplained parallels.

214 a case of a 60 year-old woman with a cystic thymoma studied with advanced tomographic imaging stydie

215 of the clonality of preleukemic thymuses and thymomas suggested that the change in pseudotyping chara

216 ngiectasia (AT) patients and in mouse Atm-/- thymoma, suggesting the involvement of V(D)J recombinati

217 sgenes, 100% of the TgTDeltaN mice developed thymoma, surprisingly with reduced latency.

218 ailable for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed

219 B cell ratios was significantly lower in the thymoma than TMG group.

220 In the validation cohort of 91 patients with thymoma, the presence of anti-interleukin-23 was associa

221 , 81 patients with IEIs, and 2 patients with thymoma; the plasma was collected before immunization, 1

222 as well as a model system for screening anti-thymoma therapeutic agents.

223 oved in four patients (mediastinal teratoma, thymoma, thymic carcinoma and thyroid cancer) and not tr

224 In the thymoma TME, CD19+ B cells, CD19+CD5+CD1d+ regulatory B

225 ns were detected around blood vessels in the thymoma TME.

226 ntraperitoneal challenge with E.G7, the EL-4 thymoma transfected with OVA, results in activation and

227 been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat.

228 lymphocytes (CTL), which lysed melanoma and thymoma tumor cells and inhibited the growth of three un

229 mphocyte differentiation often occurs in the thymoma tumor microenvironment (TME), leading to thymoma

230 B16/F10.9 murine melanoma, E.G7-OVA, or EL4 thymoma tumors elicited a CTL response to as yet unknown

231 Thymomas vary widely in terms of recurrence and influenc

232 rease in the phosphorylation of v-AKT murine thymoma viral oncogene (AKT) and enhanced the tumorigene

233 ncogenic forms of activation of v-akt murine thymoma viral oncogene homolog (AKT) and NRAS.

234 xpression of activated forms of v-akt murine thymoma viral oncogene homolog (AKT) and Ras in mouse li

235 Activation of v-akt murine thymoma viral oncogene homolog (AKT) and Ras pathways is

236 gnal-regulated kinase (ERK) and v-akt murine thymoma viral oncogene homolog (AKT) in a subset of huma

237 hatidylinositol 3-kinase (PI3K)/v-AKT murine thymoma viral oncogene homolog (AKT) pathway.

238 v akt murine thymoma viral oncogene homolog (AKT) regulation and sign

239 The protein kinase v-akt murine thymoma viral oncogene homolog (AKT), a key regulator of

240 tase and tensin homolog (PTEN), v-akt murine thymoma viral oncogene homolog (AKT), and mammalian targ

241 The kinase v-akt murine thymoma viral oncogene homolog 1 (Akt) and mammalian tar

242 on of PIK3CA by miR-10a reduced V-akt murine thymoma viral oncogene homolog 1 (AKT) phosphorylation a

243 s a major negative regulator of v-akt murine thymoma viral oncogene homolog 1 (AKT).

244 Activated v-AKT murine thymoma viral oncogene homolog 1 (AKT)/protein kinase B

245 protein signalling 4 (RGS4) and V-AKT murine thymoma viral oncogene homolog 1 (AKT1) the data are pro

246 R), the serine/threonine kinase V-Akt murine thymoma viral oncogene homolog 1 (AKT1), and the proteas

247 Sepsis inhibited the V-Akt thymoma viral oncogene homolog 1 and complex 1 of the ma

248 The proline-rich Akt (v-akt murine thymoma viral oncogene homolog 1) substrate of 40 kDa (P

249 ed hyperphosphorylation of AKT (v-akt murine thymoma viral oncogene homolog 1), a phenotype reverted

250 primary liver cancer driven by v-akt murine thymoma viral oncogene homolog and neuroblastoma RAS vir

251 ated a compensatory increase in v-akt murine thymoma viral oncogene homolog signaling and decreased e

252 of miR-155 sensitizes cells to v-akt murine thymoma viral oncogene homolog-1 inhibitors in vitro, su

253 nases such as protein kinase A, v-Akt murine thymoma viral oncogene homolog-1, glycogen synthase kina

254 ta1, protein kinase C-zeta, and v-akt murine thymoma viral oncogene homolog.

255 f the phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene homolog/mammalian target of rapam

256 ic and growth properties of the v-akt murine thymoma viral oncogene homolog/mammalian target of rapam

257 onsistent with this suggestion, v-akt murine thymoma viral oncogene homolog/protein kinase B (AKT/PKB

258 Although AKT1 (v-akt murine thymoma viral oncogene homologue 1) kinase is a central

259 hibits the HGF-induced MET-AKT (v-Akt murine thymoma viral oncogene) signaling pathway and decreases

260 rophic signaling (activation of v-akt murine thymoma viral oncogene/protein kinase B [AKT], inhibitio

261 oupled receptors (GPCRs) activate PI3K/v-AKT thymoma viral oncoprotein (AKT) to regulate many cellula

262 kinase 3beta (Gsk3beta) via inactivation of thymoma viral proto-oncogene (Akt) and 3-phosphoinositid

263 vant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tu

264 n of the insulin receptor substrate 2 (IRS2)-thymoma viral proto-oncogene (Akt) signaling pathway in

265 llular signal-regulated kinase (ERK) and the thymoma viral proto-oncogene (Akt), followed by activati

266 gram during fasting and is then inhibited by thymoma viral proto-oncogene 1 (Akt) after feeding.

267 The U3 region in a tagged LTR in one thymoma was cloned and sequenced.

268 Thymoma was detected in 19 and 11%, respectively, and lu

269 ed small-cell) was found in 77% of patients; thymoma was in 6%.

270 Type B thymoma was more likely to develop into MG, with types B

271 Survival of patients with thymoma was significantly longer than that of patients w

272 mic epithelial tumors (TET, and particularly thymoma) was more frequently associated with ICI myotoxi

273 Patients diagnosed with thymoma were selected and divided into three groups on t

274 Tumors (41.4%), mainly thymomas, were associated with CASPR2 antibodies and a p

275 gressive, complete surgical resection of all thymomas when feasible.

276 ylase inhibitors have shown some activity in thymoma whereas sunitinib may be active in TC.

277 Among the patients (most of whom had thymoma) who were known to have anti-interleukin-12, we

278 rable with those previously described for B3 thymomas, with CN gain of chromosome 1q, 5, 7 and X and